Evaluating Biomanufacturing Possibilities To Meet Patient Needs

By Nick Hutchinson, Business Steering Group Leader for Mammalian Cell Culture

FUJIFILM Diosynth Denmark

Drug sponsors must find the biomanufacturing strategy that can best accommodate uncertain and evolving demand forecasts in order to deliver innovative biologics that address blockbuster indications, rare diseases, or global pandemic threats. There are three major biologic manufacturing strategies, each with specific advantages: scale up, scale out, and continuous. Though sponsors may initially feel tied to the offering of a specific contract development and manufacturing organization (CDMO), opting to partner with a manufacturer that provides all three allows you to seamlessly pivot as demand evolves throughout different clinical phases, affording a dynamic, cost-effective plan for the life cycle of your drug. As you consider the strategy that pairs best with your needs, download the full article to examine each approach and the scenarios in which they excel.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online

FUJIFILM Diosynth Biotechnologies